Not Just any Fat for Cystic Fibrosis? Docosahexaenoic Acid in Cystic Fibrosis

Title: Not Just any Fat for Cystic Fibrosis? Docosahexaenoic Acid in Cystic Fibrosis

Volume: 2 Issue: 2

Author(s): Stephanie v. Biervliet, Jean-Pierre v. Biervliet, Eddy Robberecht and Armand Christophe

Affiliation:

Keywords: Polyunsaturated Fatty Acids, CF transmembrane conductance regulator (CFTR), Phospholipid, Eicosapentaenoic acid, inflammation

Abstract: Once the genetic defect of cystic fibrosis (CF), the most common autosomal recessive disease, was discovered, there was hope for quick positive results with gene-therapy. These did not came true, however. Recent CF mice studies by Freedman et al. demonstrated a disease reversal by high doses of docosahexaenoic acid (DHA). Although it is known for long that the same essential fatty acid imbalance with low levels of DHA is present in CF patients and that DHA has antiinflammatory actions, caution is urged to prevent false expectations when we extrapolate mice model results. This review explores the present scientific data on DHA supplementation in CF.

Cite this article as:

Biervliet v. Stephanie, Biervliet v. Jean-Pierre, Robberecht Eddy and Christophe Armand, Not Just any Fat for Cystic Fibrosis? Docosahexaenoic Acid in Cystic Fibrosis, Current Pediatric Reviews 2006; 2 (2) . https://dx.doi.org/10.2174/157339606776894658